Safety of Post-Transplant Cyclophosphamide-Based Prophylaxis in AML Patients with Pre-Existing Cardiac Morbidity Undergoing Allogeneic Hematopoietic Cell Transplantation

PTCy is feasible in AML patients with pre-existing cardiac morbidity when combined with comprehensive cardiovascular evaluation and cardio-oncology follow-up, supporting its safe use in broader patient populations with appropriate cardiologic support.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2025-09-26
DOI
https://doi.org/10.3390/cancers17193128
Citations
1
Primary Topic
Hematopoietic Stem Cell Transplantation
Type
article
Field-Weighted Citation Impact
1.77
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Safety of Post-Transplant Cyclophosphamide-Based Prophylaxis in AML Patients with Pre-Existing Cardiac Morbidity Undergoing Allogeneic Hematopoietic Cell Transplantation

Inmaculada Heras Fernando, Enric Cascos, Sara Villar, María Queralt Salas et al.
1 citations
Cancers
Hematopoietic Stem Cell Transplantation
1.77
article

Safety of Post-Transplant Cyclophosphamide-Based Prophylaxis in AML Patients with Pre-Existing Cardiac Morbidity Undergoing Allogeneic Hematopoietic Cell Transplantation

Inmaculada Heras Fernando, Enric Cascos, Sara Villar, María Queralt Salas, Mónica Baile-González, Tamara Torrado, Guillermo Ortí, Miguel Fernández de Sanmamed Girón, Sara Fernández‐Luis, Albert Esquirol, Leslie González Pinedo, José Luis López Lorenzo, Ana Pilar González, Estefanía Pérez López, Carmen Martín, Marta Luque, Adolfo Sáez, Carlos Martín‐Rodríguez, Juan José Domínguez-García, Lucía García-Mañó, Felipe Peña-Muñóz, Silvia Filaferro, Vı́ctor Navarro, Arnau Torrent Rodríguez, Manuel Jurado, Pascual Basalobre, Itziar Oiartzabal Ormtegi, Montserrat Rovira, María Jesús Pascual Cascón
article en
1 citations

Abstract

PTCy is feasible in AML patients with pre-existing cardiac morbidity when combined with comprehensive cardiovascular evaluation and cardio-oncology follow-up, supporting its safe use in broader patient populations with appropriate cardiologic support.

CancersVol. 17(19)
Hospital de Sant Pau (ES), Hospital General Universitario Morales Meseguer (ES), Hospital Universitario de Gran Canaria Doctor Negrín (ES), Grupo Español de Trasplante Hematopoyético y Terapia Celular (ES), Complejo Hospitalario de Salamanca (ES), Marqués de Valdecilla University Hospital (ES), Hospital Universitario 12 De Octubre (ES), Vall d'Hebron Institut de Recerca (ES), Hospital Regional Universitario de Málaga (ES), Hospital Clínic de Barcelona (ES), Hospital Universitario Virgen de las Nieves (ES), Hospital Universitario Reina Sofía (ES), Vall d'Hebron Hospital Universitari (ES), Hospital Universitario Fundación Jiménez Díaz (ES), Hospital Universitario Central de Asturias (ES), Instituto de Investigación Biomédica de Salamanca (ES), Clinica Universidad de Navarra (ES), Donostiako Unibertsitate Ospitalea (ES), Complexo Hospitalario Universitario A Coruña (ES), Duran i Reynals Hospital (ES), Hospital Universitario Son Espases (ES), Universitat de Barcelona (ES)
Openalex Percentile: Top 12%
Hematopoietic Stem Cell Transplantation
1.77
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.